Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in COPD (UPSTREAM-COPD)
NCT05507242Phase 2Recruiting
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Eosinophilic bronchial mucosal tissue inflammation at 20 weeks. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05507242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507242.